Partnerships & Plans
Cytox and Thermo Fisher Scientific, a leading provider of translational research and diagnostic solutions, have formed a strategic partnership to develop and commercialize blood-based genetic assays for Alzheimer’s disease (AD) risk assessment.
The Cytox variaTECT™ array and SNPfitR™ software and polygenic risk score algorithm will be used in genotyping analysis in the pioneering French INSIGHT study of AD, allowing comparison with biomarker status.
Cytox has also entered into a collaborative research arrangement with leading Australian neurodegenerative disease research partner organisations to the flagship Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL). The aim is to improve the selection of Single Nucleotide Polymorphism (SNPs) that are diagnostic and prognostic for AD.
As part of a consortium, Cytox has been awarded funding by the UK’s innovation agency, Innovate UK, through the Collaborative Research and Development (CR&D) competition ND1: ‘Diagnosis, management and stratification’. The consortium comprises Cytox, as lead, Dr Zsuzsanna Nagy (University of Birmingham), Professor John Hardy (University College London); Dr Valentina Escott-Price (University of Cardiff) will work as an expert consultant in statistical genetics to the project team. The project will evaluate and validate the clinical utility of a customized genetic variation (SNP) panel associated with the mTOR signalling and other pathways in Mild Cognitive Impairment (MCI).
Scientific Advisory Panel
We work closely with the world-renowned international experts on our Scientific Advisory Panel, such as Professor Harald Hampel, (Pierre and Marie Curie University (Sorbonne), Paris) and Professor John Hardy (University College London).
Professor Harald Hampel is a word-leading researcher with vast expertise and reputation in neurology, psychiatry and cutting-edge neuroscience research. With 20 years of experience, he has successfully developed international research programmes dedicated to Alzheimer’s diagnosis and therapeutic algorithms. In 2013 he was awarded the AXA-UPMC Chair at Université Pierre et Marie Curie, Paris, France.
Professor John Hardy is a geneticist and molecular biologist whose research interests focus on neurological disease. He was Head of the Neurogenetics Section, National Institute of Ageing, Bethesda, USA and in 2007 took up the Chair of Molecular Biology of Neurological Disease at the UCL Institute of Neurology, London. With over 23,000 citations, Professor Hardy is the most cited Alzheimer’s disease researcher in the UK (5th internationally).
Work with us
As we continue our work on the development of tests for cognitive decline, risk of developing AD or other dementias, we are looking to work with interested clinical specialists, research scientists and pharmaceutical company partners. If you would like to know more about how you could be involved in our plans, contact us at email@example.com.